JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. 2018

Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ; Public Laboratory, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.

Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased survival. Eleven TNBC cell lines were evaluated using array comparative genomic hybridization. A copy number gain was defined as an array comparative genomic hybridization log2 ratio of ≥ 1. Cell surface expression of programmed cell death ligand 1 (PD-L1) was detected using flow cytometry and compared with the median fluorescence intensity of isotype control immunoglobulin. To selectively inhibit JAK2, lentiviral vectors encoding 2 different short hairpin RNA (shRNA) were generated. JAK2, STAT1, STAT3, phosphorylated (p) STAT1, and pSTAT3 expression were measured by immunoblot. Statistical significance was defined as P < .05. The cell line HCC70 had 9p24.1 copy number amplification that was associated with both increased JAK2 and pSTAT3; however, knockdown of JAK2 inhibited cell growth independently of 9p24.1 copy number status. In TNBC cell lines with 9p24.1 gain or amplification, PD-L1 expression rapidly and strikingly increased 5- to 38-fold with interferon-γ (P < .05), and inducible PD-L1 expression was completely blocked by JAK2 knockdown and the JAK1/2 inhibitor ruxolitinib. In tumor tissue, expression of interferon-γ-related genes correlated with 9p24.1 copy number status. These data suggest that the JAK2/STAT1 pathway in TNBC might regulate the dynamic expression of PD-L1 that is induced in the setting of an inflammatory response. Inhibition of JAK2 might provide a synergistic therapy when combined with other immunotherapies in the subset of TNBC with 9p24.1 amplification.

UI MeSH Term Description Entries
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D050794 STAT1 Transcription Factor A signal transducer and activator of transcription that mediates cellular responses to INTERFERONS. Stat1 interacts with P53 TUMOR SUPPRESSOR PROTEIN and regulates expression of GENES involved in growth control and APOPTOSIS. Gamma-Activated Factor, 91 kDa,STAT-91 Protein,STAT-91 Transcription Factor,STAT1 Protein,STAT91 Transcription Factor,Signal Transducer and Activator of Transcription 1,Transcription Factor STAT91,Gamma Activated Factor, 91 kDa,STAT 91 Protein,STAT 91 Transcription Factor,Transcription Factor, STAT-91,Transcription Factor, STAT1,Transcription Factor, STAT91
D053614 Janus Kinase 2 A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS. JAK-2 Protein Tyrosine Kinase,JAK2 Protein Tyrosine Kinase,JAK 2 Protein Tyrosine Kinase
D060890 B7-H1 Antigen An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION. Antigens, CD274,PD-L1 Protein,Programmed Cell Death 1 Ligand 1 Protein,Programmed Death Ligand 1,B7-H1 Immune Costimulatory Protein,B7H1 Immune Costimulatory Protein,CD274 Antigen,PD-L1 Costimulatory Protein,Programmed Cell Death 1 Ligand 1,Antigen, B7-H1,Antigen, CD274,B7 H1 Antigen,B7 H1 Immune Costimulatory Protein,CD274 Antigens,Costimulatory Protein, PD-L1,PD L1 Costimulatory Protein,PD L1 Protein
D064726 Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN. ER-Negative PR-Negative HER2-Negative Breast Cancer,ER-Negative PR-Negative HER2-Negative Breast Neoplasms,Triple Negative Breast Cancer,Triple-Negative Breast Cancer,Triple-Negative Breast Neoplasm,Breast Cancer, Triple-Negative,Breast Cancers, Triple-Negative,Breast Neoplasm, Triple-Negative,Breast Neoplasms, Triple-Negative,ER Negative PR Negative HER2 Negative Breast Cancer,ER Negative PR Negative HER2 Negative Breast Neoplasms,Triple Negative Breast Neoplasm,Triple-Negative Breast Cancers,Triple-Negative Breast Neoplasms

Related Publications

Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
April 2014, Cancer immunology research,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
September 2015, Oncotarget,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
July 2022, Breast cancer research and treatment,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
July 2020, Experimental cell research,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
April 2021, Annals of diagnostic pathology,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
March 2022, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
January 2023, International journal of molecular sciences,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
May 2022, Journal of nanobiotechnology,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
January 2022, BioMed research international,
Meixuan Chen, and Barbara Pockaj, and Mariacarla Andreozzi, and Michael T Barrett, and Sri Krishna, and Seron Eaton, and Ruifang Niu, and Karen S Anderson
January 2021, Annals of translational medicine,
Copied contents to your clipboard!